Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
A significant proportion of healthcare professionals still tend to favor branded drugs
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Highly effective preservation solutions ensuring the safety and protection of personal care products
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Subscribe To Our Newsletter & Stay Updated